PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bumcprocBaylor University Medical Center ProceedingsAbout the JournalBaylor Health Care SystemSubmit a Manuscript
 
Proc (Bayl Univ Med Cent). 2010 April; 23(2): 139–141.
PMCID: PMC2848090

Subcutaneous β2-microglobulin amyloid shoulder nodulesin a long-term hemodialysis patient

Abstract

β2-Microglobulin accumulation with resultant tumor formation is a known albeit rare complication of long-term hemodialysis. Although these tumors may occur in various locations, subcutaneous shoulder nodules are very infrequent. We report a patient with end-stage kidney failure who had been on hemodialysis for 16 years and noted left shoulder nodules after initiation of hemodialysis; these nodules had slowly grown larger. Biopsy of one of these nodules revealed β2-microglobulin amyloidosis by histopathology, Congo red stain, electron microscopy, and immunohistochemistry.

A 75-year-old woman with end-stage kidney disease secondary to membranous glomerulonephritis on hemodialysis for 16 years was noted to have several small subcutaneous nodules on the superior surface of her left shoulder. Her past medical history included end-stage kidney disease, congestive heart failure, coronary artery disease, aortic stenosis, hypertension, chronic anemia, cerebral vascular accident, hyperlipidemia, bilateral lower extremity deep vein thrombosis, and bullous pemphigoid.

These shoulder nodules were asymptomatic and had been slowly enlarging since she had started hemodialysis (Figures (Figures11 and and22). Biopsy of one of the nodules revealed areas of acellular glassy pink amorphous material, typically seen in amyloidosis, on routine histopathology (Figure (Figure33a). A Congo red stain showed apple-green birefringence confirming the glassy pink amorphous material as amyloid (Figure (Figure33b). Electron microscopy showed typical nonbranching amyloid fibrils (Figure (Figure33c). Immunohistochemistry showed that a major amyloid component was β2-microgloblin (rabbit, polyclonal; DAKO, Carpinteria, CA) (Figure (Figure33d). These morphologic features were diagnostic of nodular amyloidosis due to β2-microglobulin deposition. Soon after this diagnosis was made, the patient elected to discontinue hemodialysis and was transferred to hospice care.

Figure 1
Several subcutaneous shoulder nodules. Biopsy of one of these nodules revealed β2-microglobulin amyloidosis.
Figure 2
Chest x-ray showing left shoulder nodule. The outline of a β2-microglobulin nodule is visible above the left shoulder (arrow).
Figure 3
Shoulder nodule. (a) Histopathology showing areas of acellular glassy pink amorphous material typically seen in amyloidosis. (b) Congo red stain showing apple-green birefringence consistent with amyloid. (c) Electron microscopy showing typical nonbranching ...

DISCUSSION

β2-Microglobulin, an 11.8-kDa low-molecular-weight protein (1) containing two antiparallel beta-pleated sheets (2), accumulates in patients undergoing long-term hemodialysis, and elevated levels are associated with amyloidosis (3).

In general, amyloidosis is a manifestation of a heterogeneous group of disorders caused by the extracellular insoluble deposition of various generally soluble proteins. Systemic amyloid deposition causes organ dysfunction and death, unless the underlying disease is successfully treated or the process is halted by therapy. Amyloidosis can be classified on the basis of the various proteins that can form amyloid. There is a growing list of amyloid diseases, with over 25 different amyloid proteins identified (4).

Serum amyloid A protein associated with chronic infection or inflammation, monoclonal immunoglobulin light chains due to plasma cell disorders, and mutated transthyretin are the most common amyloid proteins. β2-Microglobulin deposition is a less common form of amyloidosis. It typically occurs in patients with a history of chronic kidney failure undergoing long-term dialysis therapy, as in the case presented here.

The deposition of β2-microglobulin may occur as systemic amyloidosis and produce organ dysfunction and/or tumor formation. β2-Microglobulin tumors have been reported in numerous anatomic locations, including bone (2), genitalia (5), axilla (6), buttocks (710), bladder (11), dermis (12), heart, gastrointestinal tract, lungs, liver, kidneys (13), tongue (10), gastric mucosa (14), and carpal and femoral synovium (15). However, tumoral deposition of β2-microglobulin is very rare and usually occurs in patients with other manifestations of amyloidosis, mostly around the buttock region. In our case, subcutaneous shoulder nodules were a clear manifestation of amyloidosis.

β2-microglobulin, a subunit of the HL-A antigen, is found on the surface of most nucleated cells. It is released into the circulation and then removed by the kidney. Megalin, an endocytic receptor on the luminal surface of proximal tubules, binds β2-microglobulin, and it is then metabolized in kidney lysosomes (16). The synthesis rate of β2-microglobulin is similar in hemodialysis patients and normal controls. This suggests that β2-microglobulin accumulation in dialysis patients is due to decreased clearance and not increased production (1). β2-Microglobulin levels rise linearly over the first 10 years of hemodialysis and then plateau (17). Elevated serum β2-microglobulin levels in hemodialysis patients are associated with higher mortality rates (18). High-flux dialysis membranes reduce β2-microglobulin levels and are associated with decreased risk of carpal tunnel syndrome and improved survival (19, 20).

Nodular β2-microglobulin amyloid deposition should be considered in the differential diagnosis of masses or nodules in patients on long-term dialysis therapy. Diagnosis requires histological examination to show fibrillar protein deposition, which is characteristically stained with Congo red, revealing apple-green birefringence under polarization.

References

1. Floege J, Bartsch A, Schulze M, Shaldon S, Koch KM, Smeby LC. Clearance and synthesis rates of β2-microglobulin in patients undergoing hemodialysis and in normal subjects. J Lab Clin Med. 1991;118(2):153–165. [PubMed]
2. Maury CP. β2 Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients. Rheumatol Int. 1990;10(1):1–8. [PubMed]
3. Kazama JJ, Maruyama H, Gejyo F. Reduction of circulating β2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant. 2001;16(Suppl 4):31–35. [PubMed]
4. Picken MM. New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens. 2007;16(3):196–203. [PubMed]
5. Okuda I, Ubara Y, Takaichi K, Kitajima I, Motoi N, Hara S, Kokubo T. Genital β2-microglobulin amyloidoma in a long-term dialysis patient. Am J Kidney Dis. 2006;48(3):e35–e39. [PubMed]
6. Ogata H, Koiwa F, Takahashi J, Takahashi K, Shiokawa A, Kitanosono T, Kinugasa E, Taguchi S. Cystic β2-microglobulin amyloidoma in a patient on long-term hemodialysis. Clin Exp Nephrol. 2006;10(2):159–161. [PubMed]
7. Fernández-Alonso J, Rios-Camacho C, Valenzuela-Castaño A, Rocha-Castilla JL. Pseudotumoral amyloidosis of β2-microglobulin origin in the buttock of a patient receiving long term haemodialysis. J Clin Pathol. 1993;46(8):771–772. [PMC free article] [PubMed]
8. Shimizu S, Yasui C, Yasukawa K, Nakamura H, Shimizu H, Tsuchiya K. Subcutaneous nodules on the buttocks as a manifestation of dialysis-related amyloidosis: a clinicopathological entity? Br J Dermatol. 2003;149(2):400–404. [PubMed]
9. Tom Y, Htwe M, Chandra R, Smith-Behn DJ. Bilateral β2-microglobulin amyloidomas of the buttocks in a long-term hemodialysis patient. Arch Pathol Lab Med. 1994;118(6):651–653. [PubMed]
10. Sethi D, Hutchison AJ, Cary NR, Brown EA, Curtis JR, Woodrow DF, Gower PE. Macroglossia and amyloidoma of the buttock: evidence of systemic involvement in dialysis amyloid. Nephron. 1990;55(3):312–315. [PubMed]
11. Lipner HI, Minkowitz S, Neiderman G, Louis BM, Hoch BS. Dialysis-related amyloidosis manifested as masses in the buttocks. South Med J. 1995;88(8):876–878. [PubMed]
12. Floege J, Brandis A, Nonnast-Daniel B, Westhoff-Bleck M, Tiedow G, Linke RP, Koch KM. Subcutaneous amyloid-tumor of β2-microglobulin origin in a long-term hemodialysis patient. Nephron. 1989;53(1):73–75. [PubMed]
13. Gal R, Korzets A, Schwartz A, Rath-Wolfson L, Gafter U. Systemic distribution of β2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature. Arch Pathol Lab Med. 1994;118(7):718–721. [PubMed]
14. Nishi S, Ogino S, Maruyama Y, Honma N, Gejyo F, Morita T, Arakawa M. Electron-microscopic and immunohistochemical study of β2-microglobulin-related amyloidosis. Nephron. 1990;56(4):357–363. [PubMed]
15. Fenves AZ, Emmett M, White MG, Greenway G, Michaels DB. Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients. Am J Kidney Dis. 1986;7(2):130–134. [PubMed]
16. Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol. 1998;9(10):1759–1766. [PubMed]
17. Canaud B, Assounga A, Flavier JL, Slingeneyer A, Aznar R, Robinet-Levy M, Mion C. β2-Microglobulin serum levels in maintenance dialysis. What does it mean? ASAIO Trans. 1988;34(4):923–929. [PubMed]
18. Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, Inaba M, Nishizawa Y. Serum β2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 2009;24(2):571–577. [PubMed]
19. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant. 2000;15(Suppl 1):36–42. [PubMed]
20. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int. 1997;52(4):1096–1101. [PubMed]

Articles from Proceedings (Baylor University. Medical Center) are provided here courtesy of Baylor Health Care System